The Effect of SGLT-2 inhibitors and GLP-1 Agonists on Cardiovascular Disease in Patients with Type 2 Diabetes Brief Title: SGLT-2 inhibitors and GLP-1 Agonists. Authors: Amit K Dey MD 1* , Jacob Groenendyk MD 1* , Nehal N. Mehta MD; MSCE 1 , Evgenia Gourgari MD 2 *Both authors contributed equally. Author Affiliations: 1. Section of Inflammation and Cardiometabolic Disease, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda MD 2. Division of Pediatric Endocrinology, Georgetown University, Washington, DC, USA Acknowledgments: NIL Funding: This project has been partially funded with Federal funds (UL1TR001409 from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through the Clinical and Translational Science Awards Program (CTSA), a trademark of DHHS, part of the Roadmap Initiative, “Re - Engineering the Clinical Research Enterprise” (KL2 Award, Dr Gourgari) Conflict of interest relevant to this work: The authors declare no potential conflicts of interest. Dr. Mehta has received funding from the National Institutes of Health Intramural Research Program (Z01 HL-06193); is a full- time U.S. Government employee; and has received research grants from Abbvie, Janssen, Novartis Corp, and Celgene. Corresponding author: Dr. Amit Kumar Dey Department of Cardiology, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA-20814 Contact: +1 3012605366 Email: amit.dey@nih.gov Accepted Article This article is protected by copyright. All rights reserved. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/clc.23152